Outcome and Follow-up
Over one month, her skin rash and pruritus significantly improved (Figure 2) without adverse effects with dupilumab use, permitting a tapered discontinuation of prednisone. Patient’s eczema is adequately managed with dupilumab maintenance dose and continual application of emollients, and topical hydrocortisone 2.5% on face, triamcinolone 0.1% on torso as needed. In concern of seizure, long-term electroencephalogram (EEG) and further neurological workup of the patient’s blinking spells did not reveal seizures or significant findings. Six months since initiation of dupilumab, patient had an incidence of pneumonia that resolved with antibiotics but otherwise no other serious events.